Business Wire

NY-MEDIAOCEAN

6.3.2024 10:01:33 CET | Business Wire | Press release

Share
Flashtalking by Mediaocean Announces New Exclusive International Partnerships Covering 89 Markets

Mediaocean, the mission-critical platform for omnichannel advertising, today announced six new partnerships for its Creative Ad Tech platform, Flashtalking, bringing its market leading solutions to more customers in a range of key markets around the world. The agreements provision for primary ad serving, creative personalization, cross-channel measurement and verification across open web display, mobile, audio, video, digital out-of-home, and connected TV.

Collectively, the new activation partners support advertisers in 89 different countries, significantly expanding Flashtalking’s footprint following a surge in adoption after the announcement that Amazon was deprecating its Sizmek ad server. Each of these companies brings deep experience in the ad serving market, having previously supported brands and agencies using Amazon/Sizmek.

Founded in 2001 and acquired by Mediaocean in 2021, Flashtalking is the leading independent ad tech platform, bridging creative and media teams with intelligent, audience-aware insights and workflows at scale and across channels. The Flashtalking platform provides AI and automation to connect the silos between teams for more efficient production, versioning, and distribution of creative.

The new partners include Tailwind, which operates in 36 markets across Central and South Eastern Europe, the Nordics and Middle East North Africa (MENA), empowering businesses to fast track their marketing with technology integrations, strategic consultation, and professional services, as well as Box Digital, a South Africa-based digital advertising services business with customers spanning 8 sub-Saharan African countries.

A partnership with Adsmovil will bolster Flashtalking’s operations within 33 markets across Latin America (LATAM), through a business uniquely focused on Hispanic and Brazilian audiences which currently serves over 4 billion impressions per month. Meanwhile, a new relationship with Adsonice, will grow Flashtalking’s presence across Europe.

Additionally, an agreement with Escape Velocity, a digital media technology services company that supports agencies and advertisers, will scale Flashtalking in India, Korea, Bangladesh, and Sri Lanka while eTechSol will help serve customers in Pakistan.

Simon Thorne, MD EMEA for Flashtalking, commented: “We’ve seen huge appetite for a truly intelligent, dynamic approach to managing and activating creative campaigns. Advertisers need to enable deep personalization, ensuring the most relevant and impactful brand messages reach the right consumers at the right moment, and they want to do it via a single integrated platform. Today’s announcement really cements our position as being the best solution to deliver that on a global level.”

Coming in the wake of Amazon’s announcement that it will be shuttering its ad serving service, these new partnerships represented a unique opportunity to combine Flashtalking’s best-in-class advertising technology with in-market experts who can offer deep local insights and a highly mature ad serving knowledge base.

Flashtalking was recently named a winner of G2 2024 Best Software Awards for Marketing & Digital Advertising Products based on 300+ authenticated customer reviews. The platform was ranked a leader in Enterprise Creative Management Platforms, Cross-Channel, Video, Mobile, Display, and Social Media Advertising.

Georgia Brammer, MD JAPAC for Flashtalking, added, “We’re thrilled to be able to build these new relationships in so many important markets. We’ve been impressed by the drive and knowledge represented by the teams at all of these businesses. This is, on multiple fronts, a time of change in the global advertising sector and, from conversations with major advertisers, the growth potential we’re seeing in further developing this global network is already proving to be really powerful.”

Odysseas Ntotsikas, Managing Partner of Tailwind, stated, “True to Tailwind’s mission to ‘Drive business fast forward’ the power of creative has proved to be the variable with the biggest impact in an omnichannel marketer’s stack. Through this strategic partnership with global leader Flashtalking, we fortify over a decade of operational excellence in empowering hundreds of regional marketers with creative personalization and digital advertising intelligence to win the only war that matters today, the war for attention.”

Alberto Pardo, Founder & CEO of Adsmovil, said, “We, at Adsmovil, have been committed to driving relevance and value to our clients since our inception. Flashtalking furthers our mission and expands the opportunity to better serve clients with personalization based on real-time variables, driving greater congruence and resonance, and a higher advertiser ROI. We are very excited about our partnership.”

Raghu Seelamsetty, MD of Escape Velocity, added, “Escape is delighted to be partnering with Flashtalking. The partnership is well poised to take advantage of the growth of CTV and social media in these fast growing markets. Flashtalking’s market leading technology combined with Escape’s market reach and service capabilities will enable us to deliver world class solutions to our clients.”

About Flashtalking by Mediaocean

Flashtalking unleashes the power of creative to make media work better. As the leading independent platform for personalization and intelligence across all marketing channels, our Creative Ad Tech bridges the gap between creative and media. We provide AI and automation to connect the silos between teams and deliver more efficient production, versioning, and distribution of creative. Our solutions operate at scale across CTV, Video, Display, Social, Native, Audio, DOOH, and Retail Media channels. As part of Mediaocean, Flashtalking is tied into the industry’s core ad infrastructure for omnichannel planning, buying, and billing. Visit flashtalking.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305248528/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye